A director at Agree Realty Corp bought 4,850 shares at 72.150USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Larimar Therapeutics Reports Second Quarter 2025 Financial Results Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025Adolescent participants from the PK run-in study and patients with FA who have not participated in prior nomlabofusp clinical studies are currently screening and enrolling in the open label study; planning to enroll children (2 to 11 years of age) directly into the open label studyFDA recommended that the safety database include at least 30 participants with continuous study drug exposure fo...
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 21,562,500 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 2,812,500 additional...
Hawthorn Bancshares Reports Second Quarter 2025 Results JEFFERSON CITY, Mo., July 30, 2025 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK), (the “Company”), the bank holding company for Hawthorn Bank, reported second quarter 2025 net income of $6.1 million, or earnings per diluted share (“EPS”) of $0.88. Second Quarter 2025 Results Net income improved $1.5 million, or 31.8%, to $6.1 million from the second quarter 2024 (the "prior year quarter") and the efficiency ratio improved to 62.32% compared to 66.24% for the prior year quarterEPS of $0.88, an improvement ...
Hawthorn Bancshares Announces Cash Dividend JEFFERSON CITY, Mo., July 30, 2025 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK) announced today that its Board of Directors approved a quarterly cash dividend of $0.20 per common share, payable October 1, 2025 to shareholders of record at the close of business on September 15, 2025. About Hawthorn Bancshares, Inc. Hawthorn Bancshares, Inc., a financial-bank holding company headquartered in Jefferson City, Missouri, is the parent company of Hawthorn Bank, which has served families and businesses for more than 150 years. Hawthorn...
Larimar Therapeutics Announces Pricing of Underwritten Public Offering BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $60.0 million, before deducting underwriting discounts and commission...
Larimar Therapeutics Announces Proposed Underwritten Public Offering BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an ad...
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated approval BALA CYNWYD, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today ann...
Hawthorn Bancshares joins Russell 3000® and Russell 2000® Indexes in FTSE Russell’s 2025 Reconstitution Jefferson City, Mo., June 30, 2025 (GLOBE NEWSWIRE) -- Hawthorn Bancshares, Inc. (NASDAQ: HWBK), (the “Company”), the bank holding company for Hawthorn Bank, is pleased to announce they met the criteria for inclusion in the broad-market Russell 3000® Index (the “Russell 3000”) and the small-cap Russell 2000® Index (the “Russell 2000”) at the conclusion of the Russell indexes’ reconstitution. The inclusion is effective today with the opening of the U.S. market. Inclusion in the Russel...
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLAWritten FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose BLA submission seeking accelerated approval planned in the second quarter of 2026 to al...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.